This study will examine the doses, safety, and test the preliminary efficacy of hemp-derived CBD product for improving anxiety symptoms and sleep disturbances among individuals with anxiety. A 4-week, randomized, double-blind, placebo-controlled trial will be conducted to determine the safety, tolerability, preliminary efficacy, and acceptability of 50 to 150 mg/day of CBD. The treatment period will consist of a two-week titration period followed by a 2- week maintenance period. In addition, the study seeks to examine whether changes in sleep disturbances precede changes in anxiety symptoms.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Average CBD dose (mgs) used in the titration phase as reported in participant forms.
Timeframe: From enrollment to the end of titration phase at 2 weeks (Day 1 to Day 14).
Average CBD dose (mgs) used in the maintenance phase as indicated and reported in participant forms.
Timeframe: From week 2 to the end of maintenance phase at 4 weeks (Day 15 to Day 28)
Percentage of Severity of treatment-related adverse events based on the side effects/adverse events checklist, laboratory test, and self-report of unexpected ADE
Timeframe: From enrollment to the end of the study period at 12 weeks (Day 1 to Day 84)
Percentage of patients reporting Drug-Induced Liver Injury based on liver chemistries
Timeframe: From enrollment to the end of the study period at 12 weeks (Day 1 to Day 84).
Percentage of severity of depression symptoms based on the Patient Health Questionnaire-9
Timeframe: From enrollment to the end of the study period at 12 weeks (Day 1 to Day 84).
Percentage of participants reporting suicidal ideation and behavior based on the Columbia Suicide Severity Rating Scale
Timeframe: From enrollment to the end of the study period at 12 weeks (Day 1 to Day 84).